Lakefront Biotherapeutics (LKFT) Operating Expenses (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has 12 years of Operating Expenses data on file, last reported at -$74.6 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 61.2% year-over-year to -$74.6 million in Q1 2026; TTM through Mar 2026 was -$394.0 million, a 3.07% decrease from a year earlier, with the FY2025 full-year figure at -$534.8 million, down 49.16% from the prior year.
• Operating Expenses for Q1 2026 stood at -$74.6 million, up from -$125.1 million in the prior quarter.
• Over the last five years, Operating Expenses for LKFT reached as high as $619.9 million in Q4 2022 and fell as low as -$204.6 million in Q4 2023.
• Historically, Operating Expenses has averaged -$46.0 million across 5 years, with a median of -$77.8 million in 2024.
• Across the five-year window, Operating Expenses soared 95.77% in 2024 and sank 1345.7% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $619.9 million in 2022, then tumbled by 133.01% to -$204.6 million in 2023, then surged by 95.77% to -$8.7 million in 2024, then sank by 1345.7% to -$125.1 million in 2025, then jumped by 40.41% to -$74.6 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were -$74.6 million in Q1 2026, -$125.1 million in Q4 2025, and -$86.4 million in Q3 2025.